Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

BACKGROUND: Neurofibromatosis type 2 (NF2) is a genetic tumor-predisposition disorder caused by NF2/merlin tumor suppressor gene inactivation. The hallmark of NF2 is formation of bilateral vestibular schwannomas (VS). Because merlin modulates activity of the Ras/Raf/mitogen-activated protein kinase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Fuse, Marisa A, Dinh, Christine T, Vitte, Jeremie, Kirkpatrick, Joanna, Mindos, Thomas, Plati, Stephani Klingeman, Young, Juan I, Huang, Jie, Carlstedt, Annemarie, Franco, Maria Clara, Brnjos, Konstantin, Nagamoto, Jackson, Petrilli, Alejandra M, Copik, Alicja J, Soulakova, Julia N, Bracho, Olena, Yan, Denise, Mittal, Rahul, Shen, Rulong, Telischi, Fred F, Morrison, Helen, Giovannini, Marco, Liu, Xue-Zhong, Chang, Long-Sheng, Fernandez-Valle, Cristina
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6422635/
https://ncbi.nlm.nih.gov/pubmed/30615146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados